Globalfoundries Passes On IBM Chip Business, Says Report
Peter Clarke, Electronics360
July 28, 2014
IBM's efforts to sell off its chip unit appear to have broken down, with reports that Globalfoundries Inc. (Santa Clara, Calif.) is not interested in paying anywhere near IBM's asking price for its loss-making semiconductor division.
Globalfoundries has not been prepared to meet IBM's asking price, according to a Bloomberg that referenced " people familiar with the process." It is also seems clear that the two companies' interests are somewhat tangential; IBM is looking to off-load its own chip manufacturing in New York state while Globalfoundries, which is owned by an investment vehicle of the Abu Dhabi government, has its own wafer fab in upstate New York and is more interested in the IBM semiconductor patent portfolio and research knowledge that IBM has built up.
![]() |
E-mail This Article | ![]() |
![]() |
Printer-Friendly Page |
|
Related News
- TSMC Wins All Apple's A10 Chip Business, Report Says
- Will Globalfoundries be More Successful than IBM with Its Foundry Business?
- GLOBALFOUNDRIES Completes Acquisition of IBM Microelectronics Business
- GLOBALFOUNDRIES Obtains U.S. Government Clearance for IBM Microelectronics Business Acquisition
- GLOBALFOUNDRIES to Acquire IBM's Microelectronics Business
Breaking News
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- RISC-V Royalty-Driven Revenue to Exceed License Revenue by 2027
- Keysom Unveils Keysom Core Explorer V1.0
Most Popular
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- Ceva, Inc. Announces First Quarter 2025 Financial Results
- Cadence Unveils Millennium M2000 Supercomputer with NVIDIA Blackwell Systems to Transform AI-Driven Silicon, Systems and Drug Design